MLICM
SNNA

Metropolitan Life Insurance Company (MetLife)’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-5,489
Closed -$103K – 2521
2018
Q1 		$103K Buy
+5,489
New +$95.9K ﹤0.01% 2279

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s SNNA Position: Q2 2018 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q2 2018, closing a stake of 5,489 shares — an estimated $103K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in SNNA in Q1 2018 and held it in 1 quarter. The position peaked at $103K in Q1 2018. 53 funds tracked by Wall St. Rank hold SNNA as of Q2 2018.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 5,489 Sienna Biopharmaceuticals, Inc. shares in Q2 2018, an estimated $103K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Sienna Biopharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s Sienna Biopharmaceuticals, Inc. position peaked at $103K in Q1 2018.
  • 53 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q2 2018.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2018, filed 15 Aug 2018.